DRUG COMPANIES
Why is Mark Cuban leaving ‘Shark Tank’ after 15 seasons?
After 15 seasons, Mark Cuban bids farewell to Shark Tank, with his final episode airing May 16. Citing a desire to spend more time with his teenage children, Cuban departs from the show's demanding summer shooting schedule. He will continue his involvement with the Dallas Mavericks and his venture, the Mark Cuban Cost Plus Drug Company.
Piramal Pharma to stay away from prescription business in India: Nandini Piramal
Piramal Pharma is not planning to re-enter the domestic prescription formulations business, according to chairperson Nandini Piramal. Instead, the company will focus on its consumer healthcare business, potentially acquiring OTC portfolios or brands, and explore targets in its global complex hospital generics business. Piramal Pharma will continue organic expansion in its CDMO business with a capex of $100-125 million.
'Irrational' fixed dose combos harmful, may face ban: Expert panel
Several personal care products containing ingredients like aloe vera, jojoba oil, and orange oil are likely to be banned in India. An expert committee has deemed these fixed-dose combinations (FDCs) as irrational and potentially harmful to human health.
Obesity drug maker Novo Nordisk ousts CEO as competition weighs
Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in the obesity drug market. Increased competition from Eli Lilly, particularly with Zepbound surpassing Wegovy prescriptions in the U.S., and investor disappointment with Novo Nordisk's drug pipeline have contributed to a significant share price decline.
Generic pharma companies unlikely to be impacted by Trump's order to cut Rx drug prices: Report
A report suggests Indian generic drug companies may not be affected by US President Donald Trump's order. The order aims to lower US prescription drug prices. It will match them to those of other developed nations. The 'Most-Favoured-Nation' price model will be introduced. This model will cover Medicare and Medicaid. The order may face legal challenges.
Govt may mandate QR codes on vaccines, key drugs to curb counterfeits
The government is considering mandating bar codes or QR codes on labels for vaccines, antimicrobials, narcotics, psychotropic substances, and additional cancer drugs to combat counterfeiting. Furthermore, the inclusion of excipient details on medicine strips for 300 drug formulations under Schedule H2 is being deliberated.
- Go To Page 1
Chill, trimmed pill prices won't hurt us
Donald Trump's executive order targeting international consumer price parity for prescription drugs in the US faces implementation challenges and potential legal battles. While unlikely to significantly impact Indian generic drug exporters, the order aims to increase imports from developed economies.
Jamie Lee Curtis regrets undergoing plastic surgery at just 25, reveals the reason behind her decision
Jamie Lee Curtis recently recalled the reason that she claims had led her to getting the cosmetic procedure. She was just 25 in the 1980s when she decided to opt for the surgery. The Hollywood legend also mentioned about the after-effects of the operation.
Donald Trump’s order to lower prices may benefit generics, says Cipla CEO
Cipla anticipates that Donald Trump's order to lower US drug prices could favor generic drug companies like itself. The company reported a strong Q4 performance with a 30% increase in net profit. Cipla is optimistic about growth in India, particularly in the weight-loss drug market, and is exploring both organic and inorganic expansion opportunities.
US govt order unlikely to impact on Indian pharma players, says Cipla
Umang Vohra of Cipla says that the US order to lower drug costs will likely target branded drugs. He believes generic drug prices are already competitive. Vohra also states that potential US tariffs on pharmaceutical imports are not expected to significantly impact Cipla's business. He mentions that discussions between the US and Indian governments are ongoing.
Trump wants to slash prescription drug prices in US. What it means for your pharmacy bill
Donald Trump has signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement.The order gives drugmakers price targets in the next 30 days, and will take further action to lower prices if those companies do not make "significant progress" toward those goals. The question that remains is that how Trump's directive to pharma companies may affect your pharmacy bill.
Donald Trump's pharma pricing diktat details and how it can be legally challenged
President Trump signed an executive order aimed at lowering U.S. drug prices to match those of other countries, prompting industry concerns and potential legal challenges. The order directs action if drugmakers don't make progress, including considering imports and export restrictions. While trade groups criticized the move, shares of drugmakers rallied, suggesting skepticism about its implementation.
Trump order unlikely to impact domestic generic industry working on razor-thin profits
The US order to lower prescription drug prices is unlikely to impact Indian generic drugmakers, as they already operate on low margins, experts say. The move mainly affects innovator pharma companies required to align prices with global benchmarks.
Lupin launches generic version of kidney disorder treatment drug in US
Lupin Ltd has launched generic Tolvaptan tablets in the US, after receiving USFDA approval. These tablets, with strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, are bioequivalent to Jynarque and indicated for slowing kidney function decline in adults with ADPKD. Lupin holds exclusive first-to-file status, granting them 180-day generic drug exclusivity.
Trump’s drug price order raises alarm bells for Indian pharma
President Trump's plan to lower US prescription drug prices by aligning them with other countries could impact Indian pharmaceutical companies, which heavily rely on the US market for revenue. While primarily targeting innovator drugmakers, the move may squeeze Indian generic firms, potentially leading to margin pressure and strategic adjustments.
Pharma stocks rally up to 4%, but will Trump order really have minimal impact?
The Nifty Pharma index gained around 2% on Tuesday, defying the broader market trend, as the Nifty slipped nearly 0.5% amid profit-booking following Monday’s sharp rally — the strongest single-day gain in the past four years for the benchmark indices.
Pharma stocks decline amid Trump’s prescription drug price cuts announcement
The Nifty Pharma Index ended 0.2% higher Monday after tumbling almost 2.4% earlier in the day in response to Trump's remarks. The Sensex and Nifty jumped nearly 4%-posting their biggest single-day gains in four years. Of the 20 stocks in Nifty Pharma, 13 gained and seven declined.
US pharma stocks gain up to 5% on Trump's move to slash drug prices
President Trump plans to sign an executive order mandating drugmakers to align U.S. drug prices with those of other countries, setting price targets within 30 days. If companies fail to make significant progress within six months, the government will consider measures like importing drugs and export restrictions.
'We're no longer paying...': Trump sets deadline for pharma firms to lower US prescription drug costs in new order
Donald Trump signed an order to cut drug costs. Pharma companies have 30 days to comply. Otherwise, the government will limit payments. The order directs the health department to negotiate prices. US drug prices will be linked to lower costs in other countries. Trump claims this will save taxpayers trillions. He accuses other countries of exploiting America.
What is Trump's ‘most favored nation’ drug pricing policy and how will it reduce costs? Explained
President Donald Trump on Sunday announced that he will be signing an executive order to reduce prescription drug prices in the US. The 78-year-old mentioned his ‘Most Favored Nation’ (MFN) drug pricing policy, saying it will bring down prices by 30% to 80%. “I will be instituting a MOST FAVORED NATION’S POLICY whereby the United States will pay the same price as the Nation that pays the lowest price anywhere in the World," he wrote.
Trump promises to order that the US pay only the price other nations do for some drugs
Donald Trump announced he will sign an executive order aiming to lower drug costs by tying Medicare prices for certain medications administered in doctor's offices to the lowest prices paid by other countries. This "most favored nation" policy, targeting drugs covered under Medicare Part B, seeks to address the disparity in U.S. drug prices compared to other nations.
Pharma stocks in focus as Trump announces cut in prescription drug prices by 59%
Trump announced that the U.S. would adopt a "Most Favored Nation" policy, under which it would pay the same price for prescription drugs as the country with the lowest rates globally. “Our Country will finally be treated fairly, and our citizens' healthcare costs will be reduced by numbers never even thought of before,” he said in a post.
India has not accepted 'data exclusivity' demand by UK to protect generic drug firms
India has declined the UK's request for a 'data exclusivity' clause in their free trade agreement to safeguard its domestic generic drug industry. This decision mirrors a previous rejection of a similar demand from the EFTA bloc. The move aims to protect the flourishing generic drug sector, a key player in India's exports, from potential restrictions on producing affordable medicines.
Improving geopolitical cues mark a major positive for equities: Sandip Sabharwal
From a very negative environment we seem to be moving to a more constructive, positive environment in a very rapid speed. So, as things play out globally, it could have a positive impact on risky assets, mostly equities, etc, and could create some sort of corrections in gold, and other safe heaven assets.
Pie in the sky? Trump’s executive order on pharma unlikely to see the light of day: N Jayakumar
N Jayakumar of Prime Securities deems the US executive order on pharma prices as unrealistic and anticipates legal challenges. He emphasizes the dominance of large pharmacy chains and their markups on generic drugs, suggesting that inefficient distribution, rather than price control, is the core issue. Reducing distribution costs is key to making drugs more affordable for consumers.
Trump's drug order sparks concern for India's pharma policy: GTRI
Donald Trump's "Most Favored Nation" pricing rule, aimed at significantly lowering U.S. drug prices, is expected to have global repercussions. The move could pressure pharmaceutical companies to seek higher revenues in markets like India, potentially impacting its pharmaceutical policies.
Biocon plans $150-million capex in two years
Biocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 million to generics. Fueled by strong generics growth and biosimilar progress, Q4 net profit surged 153%. The company launched key medications in the US and UK, focusing on peptide portfolios and biosimilars for future growth, with analysts maintaining a positive outlook.
Drug companies to pay Hawaii USD 700 million to settle Plavix blood thinner lawsuit
Pharmaceutical companies Bristol Myers Squibb and Sanofi have agreed to pay Hawaii USD 700 million to settle a lawsuit concerning the blood thinner Plavix. The lawsuit alleged the companies failed to adequately warn about a diminished response to Plavix in certain patients, particularly non-Caucasians. While the companies do not admit wrongdoing, the settlement resolves the litigation before an appeal.
FDC recalls over 60,000 bottles of ophthalmic solution in US
FDC Ltd is recalling over 60,000 bottles of Timolol Maleate Ophthalmic Solution, a generic glaucoma medication, in the US market. The USFDA reported the recall, initiated on April 18, is due to a defective container issue where the bottle's spike was lodged in the nozzle, preventing solution dispensing.
Load More
